Biotech Values

[DewDiligence]

FDA approves BXLT’s Vonvendi for von Willebrand disease:

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476065.htm

Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with VWD.

VWD is the most common inherited bleeding disorder, affecting approximately 1 percent of the U.S. population. Men and women are equally affected by VWD, which is caused by a deficiency or defect in von Willebrand factor, a protein that is critical for normal blood clotting.

There are plasma-derived products for VWD, but these will likely be superseded in due course by the recombinant Vonvendi.